Cytotoxic effects of a novel pyrazolopyrimidine derivative entrapped in liposomes in anaplastic thyroid cancer cells in vitro and in xenograft tumors in vivo

Endocrine-Related Cancer

Volumn 15, Issue 2, 2008, Pages 499-510

  Celano, M ^a   Schenone, S ^b   Cosco, D ^a   Navarra, M ^c   Puxeddu, E ^d   Racanicchi, L ^d   Brullo, C ^b   Varano, E ^a   Alcaro, S ^a   Ferretti, E ^e   Botta, G ^f   Filetti, S ^e   Fresta, M ^a   Botta, M ^f   Russo, D ^a  

^a UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

^c UNIVERSITY OF MESSINA   (Italy)

^d UNIVERSITY OF PERUGIA   (Italy)

^e SAPIENZA UNIVERSITY OF ROME   (Italy)

^f UNIVERSITY OF SIENA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

1 (2 CHLORO 2 PHENYLETHYL) 6 (METHYLTHIO) N (2 PHENYLETHYL) 1H PYRAZOLO[3,4 D]PYRIMIDIN 4 AMINE; CYCLIN D1; EPIDERMAL GROWTH FACTOR; MITOGEN ACTIVATED PROTEIN KINASE; N BENZYL 1 (2 CHLORO 2 PHENYLETHYL) 6 (METHYLTHIO) 1H PYRAZOLO[3,4 D]PYRIMIDIN 4 AMINE; PYRAZOLOPYRIMIDINE DERIVATIVE; SI 34; SI 35; STEROID RECEPTOR COACTIVATOR 1;

ANAPLASTIC CARCINOMA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; CYTOTOXICITY; ENZYME ACTIVATION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIPOSOMAL DELIVERY; MOUSE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SCID MOUSE; THERAPY EFFECT; THYROID CANCER; TREATMENT OUTCOME; TREATMENT RESPONSE; XENOGRAFT;

ANIMALS; ANNEXIN A5; APOPTOSIS; CELL DIVISION; CELL LINE, TUMOR; HUMANS; LIPOSOMES; MICE; MICE, INBRED NOD; MICE, SCID; NEOPLASM INVASIVENESS; PYRAZOLES; PYRIMIDINES; STAT1 TRANSCRIPTION FACTOR; THYROID NEOPLASMS; TRIAZOLES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 45849100944     PISSN: 13510088     EISSN: None     Source Type: Journal    
DOI: 10.1677/ERC-07-0243     Document Type: Article

References (43)

1. Aiello A, Pandini G, Frasca F, Conte E, Murabito A, Sacco A, Genua M, Vigneri R & Belfiore A 2006 Peroxisomal proliferator-activated receptor-γ agonists induce partial reversion of epithelial-mesenchymal transition in anaplastic thyroid cancer cells. Endocrinology 147 4463-4475.
2. Ain KB 1998 Anaplastic thyroid carcinoma: behavior, biology, and therapeutic approaches. Thyroid 8 715-726.
3. Alcaro S, Marino T, Ortuso F & Russo N 2007 Conformational behaviour of antineoplastic peptides Dolastatin 10 and Dolastatin 15 from Monte Carlo and molecular dynamics simulations. International Journal of Quantum Chemistry 107 318-325.
4. Alvarez RH, Kantarjian HM & Cortes JE 2006 The role of Src in solid and hematologic malignancies: development of new-generation Src inhibitors. Cancer 107 1918-1929.
5. Angelucci A, Schenone S, Gravina GL, Muzi P, Festuccia C, Vicentini C, Botta M & Bologna M 2006 Pyrazolo[3,4-d]pyrimidines c-Src inhibitors reduce epidermal growth factor-induced migration in prostate cancer cells. European Journal of Cancer 42 2838-2845.
6. Ball DW, Jin N, Rosen M, Dackiw A, Sidransky D, Xing M & Nelkin BD 2007 Selective growth inhibition in BRAF mutant thyroid cancer by the mitogen-activated protein kinase 1/2 inhibitor AZD6244. Journal of Clinical Endocrinology and Metabolism 92 4712-4718.
7. Bjorge JD, Jakymiw A & Fujita DJ 2000 Selected glimpses into the activation and function of Src kinase. Oncogene 19 5620-5635.
8. Braga-Basaria M, Hardy E, Gottfried R, Barman KD, Saji M & Ringel MD 2004 17-Allylamino-17-demethoxygeldanamycin activity against thyroid cancer cell lines correlates with Heat shock protein 90 levels. Journal of Clinical Endocrinology and Metabolism 89 2982-2988.
9. Calvagno MG, Celia C, Paolino D, Cosco D, Iannone M, Castelli F, Doldo P & Fresta M 2007 Effects of lipid composition and preparation conditions on physical-chemical properties, technological parameters and in vitro biological activity of gemcitabine-loaded liposomes. Current Drug Delivery 4 89-101.
10. Carlomagno F, Vitagliano D, Guida T, Basolo F, Castellone MD, Melillo RM, Fusco A & Santoro M 2002 The kinase inhibitor PP1 blocks tumorigenesis induced by RET oncogenes. Cancer Research 62 1077-1082.
11. Carlomagno F, Vitagliano D, Guida T, Basolo F, Castellone MD, Melillo RM, Fusco A & Santoro M 2003 Efficient inhibition of RET/papillary thyroid carcinoma oncogenic kinases by 4-amino-5-(4-chloro-phenyl)-7-(t-butyl) pyrazolo[3,4-d]pyrimidine (PP2). Journal of Clinical Endocrinology and Metabolism 88 1897-1902.
12. Carraro F, Pucci A, Naldini A, Schenone S, Bruno O, Ranise A, Bondavalli F, Brullo C, Fossa P, Menozzi G et al. 2004 Pyrazolo[3,4-d]pyrimidines endowed with antiproliferative activity on ductal infiltrating carcinoma cells. Journal of Medicinal Chemistry 47 1595-1598.
13. Celano M, Calvagno MG, Bulotta S, Paolino D, Arturi F, Rotiroti D, Filetti S, Fresta M & Russo D 2004 Cytotoxic effects of Gemcitabine-loaded liposomes in human anaplastic thyroid carcinoma cells. BMC Cancer 4 63.
14. Copland JA, Marlow LA, Kurakata S, Fujiwara K, Wong AK, Kreinest PA, Williams SF, Haugen BR, Klopper JP & Smallridge RC 2006 Novel high-affinity PPARγ agonist alone and in combination with paclitaxel inhibits human anaplastic thyroid carcinoma tumor growth via p21WAF1/CIP1. Oncogene 25 2304-2317.
15. Damante G, Russo D, Foti D, Grasso G & Filetti S 1990 Effect of thyrotropin and cAMP on FRTL-5 cell growth in a serum free medium. Journal of Endocrinological Investigation 13 397-402.
16. Donnini S, Monti M, Castagnini C, Solito R, Botta M, Schenone S, Giachetti A & Ziche M 2006 Pyrazolo-pyrimidine-derived c-Src inhibitor reduces angiogenesis and survival of squamous carcinoma cells by suppressing vascular endothelial growth factor production and signaling. International Journal of Cancer 120 995-1004.
17. Erpel T & Courtneidge SA 1995 Src family protein tyrosine kinases and cellular signal transduction pathways. Current Opinion in Cell Biology 7 176-182.
18. Fagin JA 2004 How thyroid tumors start and why it matters: kinase mutants as targets for solid cancer pharmacotherapy. Journal of Endocrinology 183 249-256.
19. Fagin JA, Matsuo K, Karmakar A, Chen DL, Tang SH & Koeffler HP 1993 High prevalence of mutations of the p53 gene in poorly differentiated human thyroid carcinomas. Journal of Clinical Investigation 91 179-184.
20. Gibbs JB 2000 Mechanism-based target identification and drug discovery in cancer research. Science 287 1969-1973.
21. Hoelting T, Tezelman S, Siperstein AE, Duh Q-Y & Clark OH 1995 Biphasic effects of thyrotropin on invasion and growth of papillary and follicular thyroid cancer in vitro. Thyroid 5 35-40.
22. Kundra P & Burman KD 2007 Thyroid cancer signalling pathways and use of targeted therapy. Endocrinology and Metabolism Clinics of North America 36 839-853.
23. Leo A & Hansch C 1971 Linear free energy relations between partitioning solvent systems. Journal of Organic Chemistry 36 1539-1544.
24. Luong QT, O' Kelly J, Braunstein GD, Hershman JM & Koeffler HP 2006 Antitumor activity of Suberoylanilide hydroxamic acid against thyroid cancer cell lines in vitro and in vivo. Clinical Cancer Research 12 5570-5577.
25. May TS 2003 Gleevec: tailoring to fit. Drug Discovery Today 8 188-189.
26. Mohamadi F, Richards NGJ, Guida WC, Liskamp R, Lipton M, Caufield C, Chang G, Hendrickson T & Still WC 1990 MacroModel - an integrated software system for modeling organic and bioorganic molecules using molecular mechanics. Journal of Computational Chemistry 11 440-467.
27. Morisi R, Celano M, Tosi E, Schenone S, Navarra M, Ferretti E, Costante G, Durante C, Botta G, Brullo C et al. 2007 Growth inhibition of medullary thyroid carcinoma cells by pyrazolo-pyrimidine derivates. Journal of Endocrinological Investigation 30 RC31-RC34.
28. Navarra M, Romano C, Lorenzon T, Rotiroti D & Di Renzo G 2001 Ethanol exposure inhibits the cytotoxic effect induced by gp120 in CHP100 human neuroblastoma cells. Journal of Neuroscience Research 65 354-361.
29. Nobuhara Y, Onoda N, Yamashita Y, Yamasaki M, Ogisawa K, Takashima T, Ishikawa T & Hirakawa K 2005 Efficacy of epidermal growth factor receptor-targeted molecular therapy in anaplastic thyroid cancer cell lines. British Journal of Cancer 92 1110-1116.
30. Ohta K, Pang XP, Berg L & Hershman JM 1996 Antitumor actions of cytokines on new human papillary thyroid carcinoma cell lines. Journal of Clinical Endocrinology and Metabolism 81 2607-2612.
31. Ouyang B, Knauf JA, Smith EP, Zhang L, Ramsey T, Yusuff N, Batt D & Fagin JA 2006 Inhibitors of Raf kinase activity block growth of thyroid cancer cells with RET/PTC or BRAF mutations in vitro and in vivo. Clinical Cancer Research 12 1785-1793.
32. Parsons JT & Parsons SJ 1997 Src family protein tyrosine kinases: cooperating with growth factor and adhesion signaling pathways. Current Opinion in Cell Biology 9 187-192.
33. Pasieka JL 2003 Anaplastic thyroid cancer. Current Opinion in Oncology 15 78-83.
34. Pestell RG, Albanese C, Reutens AT, Segall JM, Lee RJ & Arnold A 1999 The cyclin and cyclin-dependent kinase inhibitors in hormonal regulation of proliferation and differentiation. Endocrine Reviews 20 501-534.
35. Russo D, Arturi F, Bulotta S, Pellizzari L, Filetti S, Manzini G, Damante G & Tell G 2001 Ape1/Ref-1 expression and cellular localization in human thyroid carcinoma cell lines. Journal of Endocrinological Investigation 24 RC10-RC12.
36. Russo D, Bisca A, Celano M, Talamo F, Arturi F, Scipioni A, Presta I, Bulotta S, Ferretti E, Filetti S et al. 2005 Proteomic analysis of human thyroid cell lines reveals reduced nuclear localization of Mn-SOD in poorly differentiated thyroid cancer cells. Journal of Endocrinological Investigation 28 137-144.
37. Sadzuka Y & Hirota S 1998 Does the amount of an antitumor agent entrapped in liposomes influence its tissue distribution and cell uptake? Cancer Letters 131 163-170.
38. Sadzuka Y, Kishi K, Hirota S & Sonobe T 2003 Effect of polyethyleneglycol (PEG) chain on cell uptake of PEG-modified liposomes. Journal of Liposome Research 13 157-172.
39. Schenone S, Bruno O, Ranise A, Bondavalli F, Brullo C, Fossa P, Mosti L, Menozzi G, Carraro F, Naldini A et al. 2004a New pyrazolo[3,4-d]pyrimidines endowed with A431 antiproliferative activity and inhibitory properties of Src phosphorylation. Bioorganic and Medicinal Chemistry Letters 14 2511-2517.
40. Schenone S, Bruno O, Bondavalli F, Ranise A, Mosti L, Menozzi G, Fossa P, Donnini S, Santoro A, Ziche M et al. 2004b Antiproliferative activity of new 1-aryl-4-amino-1H-pyrazolo[3,4-d]pyrimidine derivatives toward the human epidermoid carcinoma A431 cell line. European Journal of Medicinal Chemistry 39 939-946.
41. Tardi PG, Gallagher RC, Johnstone S, Harasym N, Webb M, Bally MB & Mayer LD 2007 Coencapsulation of irinotecan and floxuridine into low cholesterol-containing liposomes that coordinate drug release in vivo. Biochimica et Biophysica Acta 1768 678-687.
42. Wiseman SM, Masoudi H, Niblock P, Turbin D, Rajput A, Hay J, Bugis S, Filipenko D, Huntsman D & Gilks B 2007 Anaplastic thyroid carcinoma: expression profile of targets for therapy offers new insights for disease treatment. Annals of Surgical Oncology 14 719-729.
43. Zwick E, Bange J & Ullrich A 2001 Receptor tyrosine kinase signalling as a target for cancer intervention strategies. Endocrine-Related Cancer 8 161-173.